CRBU - Caribou Biosciences to Present Preclinical Data on CB-012 an Allogeneic Anti-CLL-1 CAR-T Cell Therapy at the American Association for Cancer Research (AACR) Annual Meeting | Benzinga
BERKELEY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that preclinical data from CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML), will be presented as a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10, 2024 in San Diego.
Details of the poster presentation are as follows:
Title: Preclinical evaluation of CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy, that exhibits specific and potent cytotoxicity in acute myeloid leukemia (AML) xenograft models
Presenter: Brian Francica, PhD
Date and time: Tuesday, April 9, 2024, 1:30 - 5:00 pm PT
Session: Adoptive Cellular Therapy 2
Location: San Diego Convention Center, poster section 40, poster board 14
Abstract number: 6323
The poster will be available on the Scientific Publications page of Caribou's website on Tuesday, April 9, 2024 at 1:30 pm PT.
About CB-012
CB-012 is a product candidate from Caribou's allogeneic CAR-T cell therapy platform being evaluated in the AMpLify Phase 1 clinical trial in patients with relapsed or refractory acute myeloid leukemia (r/r AML). CB-012 is an anti-CLL-1 CAR-T cell therapy engineered with five genome edits, enabled by Caribou's patented next-generation CRISPR technology platform, which uses Cas12a chRDNA genome editing to significantly improve the specificity of genome edits. To Caribou's knowledge, CB-012 is the first allogeneic CAR-T cell therapy with both checkpoint disruption, through ...